Simplifies the diagnostic by professionals / researchers.

What can RetmarkerAMD offer?

AMD Research is used for the assisted grading of fundus images from patients with Age-related Macular Degeneration (AMD)

previous arrow
next arrow

Advantages of
RetmarkerAMD Research

Significant Time Savings

at least 35% faster according to preliminary studies

Reduces risk of error on lesion area calculation
Improves Graders’ effectiveness
Allows multimodal analysis of retinal images
Produces standardized and detailed records in Excel format that allow easy data mining and statistical analysis
Download Product Brochure


Marques, J.P. et al. "Validation of RetmarkerAMD as a semiautomatic grading software for AMD." Nature: Eye (2019)


J Q Gil et al. "Clinical features and long-term progression of reticular pseudodrusen in AMD: findings from a multicenter cohort", Nature: Eye (2017) 31, 364–371


Silva R et al. "AMD and Risk Factors for the Development of Choroidal Neovascularisation in the Fellow Eye: A 3-Year Follow-Up Study", Ophthalmologica 2011; 226, no. 3: 110-118


Cachulo ML et al. "Early markers of choroidal neovascularization in the fellow eye of patients with unilateral exudative AMD", Ophthalmologica 2011; 225:144-149

Gil J. et al
"Clinical features and long-term progression of reticular pseudodrusen in AMD: findings from a multicenter cohort"

Marques J. et al.
"Reticular pseudodrusen and the five-year risk of progression for late AMD"

Silvia N. Simao et al.
"Validation of Retmarker AMD for Quantification of Early Age-Related Maculopathy Features"

Silva R. et al
"Digital Vs manual evaluation in early ARM"

T. Santos et al.
"Macular Changes Follow-Up in Dry AMD Using the RetMarker. "

T. Santos et al.
"Automated Detection of Macular Changes in Dry AMD Using the Retmarker"

“This new tools allows for a faster and more precise way to conduct a detailed analysis of the lesions associated with the early and late forms of Age-related Maculopathy. It promotes the creation of a broad basis for the assertive discussion on the prognostic values of different lesions found on this disease.”

Professor Rufino Silva
Principal Investigator of the Centre for Clinical Trials (CEC) at AIBILI

Interested? Let's talk.